Abstract
Administration for respiratory tract infection. It is active against many common pathogens of the respiratory tract, including Hemophilus influenzae, St repto coccus pneumoniae, Moraxella (Branhamella) catarrhalis, and P. aeruginosa. About 900Jo of Pseudomonas aeruginosa strains are inhibited by dose of less than 1 mcg/ mL of ciprofloxacin. Some activity against Legionella and mycobacteria organisms has also been demonstrated. Ciprofloxacin has been shown to be effective against beta-lactamase-producing organisms and methicillinresistant Staphylococcus aureus (both methicilinsusceptible, and to a lesser extent. methicillinresistant strains) .
The role of oral ciprofloxacin in the treatment of respiratory infections has been reviewed in a previous issue of this journal. 1 The oral formula is useful in managing acute bacterial exacerbations of chronic obstructive pulmonary disease and bacterial lower respiratory tract infections in diabetic, alcoholic patients and for treating elderly patients with respiratory tract infections, including nosocomial pneumonias.
This article reviews the current applications of sequential intravenous/oral ciprofloxacin in the treatment of lower respiratory tract infections. This review is based on the author's personal experience and a review of the current literature. The focus will be on the role of sequential IV / PO ciprofloxacin as monotherapy in serious lower respiratory tract infection, particularly nosocomial pneumonia with associated cost benefits.
Page 18 -JJMA: Volume 24, 1992 Nosocomial pneumonia According to the National Nosocomial Infections Surveillance (NNIS) System, nosocomial pneumonia is the second leading cause of hospital-acquired infections, accounting for approximately 130Jo-180Jo of all nosocomial infections in the United States. Hospital-acquired pneumonia occurs at a frequency of 0 .6-1.0 episodes per 100 hospitalizaions and in 18% of postoperative patients. Intubated patients may have rates of pneumonia 7-to 12-fold higher than usual patients without a respiratory therapy device. 2 
Etiology of nosocomial pneumonia
Gram-negative bacilU are implicated in more than 60% of the reported cases of nosocomial pneumonia. Amongst these bacilli, Pseudomonas aeruginosa accounts for 17%, followed by Enterobacter spp (10%), Klebsiella pneumoniae (7%), Escherichia coli (60Jo), Haemophilus influenza (6%), Serratia marcescans (4.5%). Staphylococcus aureus comprises 14% of all nosocornial pneumonia pathogens with a particularly high prevalence in burn and surgical intensive care unit patients with wound infections. Streptococcus pneumoniae (3%), Haemophilus influenza and Branhamella catarrhalis are often present in elderly patients with chronic lung disease. 1 Mortality. morbidity and cost of nosocomial pneumonla Crude mortality rates for nosocornial pneumonia may range from 20% to SOOJo with an attributable mortality of 330Jo.l Hospital-acquired pneumonia may prolong hospitalization by 8-9 daysl and may increase the duration of mechanical ventilation or intensive care unit stay thereefold. Based on an estimated 40 million hospitalizations per year in the United States, the annual direct cost of diagnosing and treating nosocomial pneumonia exceeds $2 billion.•
Treatment of nosocomial pneumonia Combination vs Monotherapy
In contrast to community-acquired pneumonias where monotherapy with antibiotics is often prescribed, based on the most likely causative organism, therapy of nosocomial pneumonia is often given as a combination of antibiotics. The combination used is for synergy and to adequately treat the wide range of organisms often found in nosocornial pneumonia, particularly in patients who have multiple comorbidity risk factors. Recommendations for treatment are: third-generation cephalosporin, or extended spectrum penicillins, or penicillinase-resistant penicillins, combined with one of the aminoglycosides like gentamicin, amikacin or tobramycin.' (Erythromycin must be added whenever Legionella is suspected.) Over the past decade, a number of studies were done to evaluate the effectiveness of monotherapy against combination therapy for treatment of nosocomial pneumonias. Some of the results of these studies are tabulated in Table 2 . Subsequently, other studies using monotherapy with imipenem, aztreonam, third-generation cephalosporin (ceftazidime), ticarcillin/clavulanic acid were completed and showed overall success rates of 7711/o-9611/o.
-u
Other observations made from these studies showed that superinfection was higher with combination therapy (180Jo vs 120Jo), colonization rates were higher in patients receiving monotherapy (300/o vs 2011/o), and persistence of Pseudomonas sp. , Enterobacter sp. and Serratia sp. sometimes led to the development of resistance amongst these organisms. Thus, it appears that monotherapy as treatment of nosocomial pneumonia is effective, particularly with the use of the recently introduced potent cephalosporins, monobactams, and carbipenems.
Fluoroqoinolones as monotberapy for nosocomial pneumonia
In view of the excellent in vitro susceptibility of the common nosocomial pneumonic pathogensPseudomonas aeruginosa, Enterobacter species, Klebsiella pneumonia, Escherichia coli, Haemophilus influenzae, Serratia marcescans, Staphylococcus aureus -against ciprofloxacin (Table  3) , a number of studies were done in the United States and other countries to evaluate the safety and efficacy of sequential intravenous/oral (IV /PO) ciprofloxacin as a monotherapy in the treatment of nosocomial penumonia. The results of some of these clinical trials are summarized in the accompanying Table 4 .
In reviewing the sixteen studies listed in Table 3 and 4, several features become obvious: a. The sequential intravenous/oral ciprofloxacin achieves a high, acceptable success rate in the treatment of serious lower respiratory tract infections. The approved intravenous dose of ciprofloxacin is 400 mgm every 12 hours.
b. A common observation in most of the studies which merits special attention is the shorter duration of IV ciprofloxacin compared to the parenteral comparative drug. This, perhaps, results from the advantage which IV /PO ciprofloxacin offers regarding a predictable response since the spectrum of activity is the same for the IV and oral formulations. As a result, cost reduction can be a significant benefit of sequential therapy. These factors simplify the clinical decision to switch to an oral drug and represent an advantage of sequential ciprofloxacin therapy over traditional therapy with aminoglycosides or thirdgeneration cephalosporins. For example, in one study, 22 the 56 ceftazidime-treated patients received, on an average, seven days of intravenous ceftazidime, followed by various currently available broad spectrum oral antibiotics for a variable period of time. The 66 cirprofloxacin-treate patients, on an average, received six days of intravenous ciprofloxacin, followed by an average of five days of oral ciprofloxacin, 500 mg twice daily. The daily cost of intravenous ceftazidime at Nassau County Medical Center is approximately $78/day, while oral 500 mgm twice/daily ciprofloxacin costs $4/day. Thus, in the ceftazidime group, 56 patients who received one extra day of intravenous ceftazidime, the extra cost was $4,144 (56 patients x 74). c. From a pulmonologist's point of view, ciprofloxacin is very effective as monotherapy for Gramnegative infections of the lower respiratory tract. For staphylococcal infections, fluoroquinolones may also be effective. However, there are better drugs with a better spectrum of activity against anaerobes. Ciprofloxacin ls quite effective for H. influenzae infection, as well M. catarrhalis, a common pathogen in respiratory infections. For S. pneumoniae infection, penicillin remains the drug of choice in healthy patients. However, in polymicrobial infections in which the pathogen is not identified prior to the start of therapy, ciprofloxacin is effective if S. pneumoniae is present. The sequential intravenous-to-oral ciprofloxacin regime is effective for serious LRTls. It is possible to begin the IV formulation in a severely A total of 94 patients with serious bacterial infections were included. Clinical and bacterial cure was 92 and 73"lo resp.
!Nosocomial LRTI, elderly critically ill in the ICU.
Gram-negative LRTI with multiple-resistant organisms only were included. Elderly ICU patients with malnutriilJ patient and, after a few days when the patient improves, switch to oral ciprofloxacin without the concern of changing dosages or that the new antimicrobial may not have the same spectrum of activity for the pathogens involved in the infection being treated. d. Ciprofloxacin with its extended antimicrobial spectrum -antipseudomonal, antistaphylococcal, antienterobacteroceal -has proved to be a safe and effective therapeutic agent for nosocomial pneumonia caused by multiresistant organisms. The ability to switch to the oral form should allow ciprofloxacin to be a convenient and cost-effective alternative to current therapeutic regimes which require continued intravenous use with attendant risk of phlebitis and sepsis.
Areas of concern: emergence of resistance Sporadic emergence of resistance occurs more often in Staphylococcus aureus and Pseudomonas aeruginosa -both with modest susceptibility against ciprofloxacin in the range of 0.5-2 ug/ml'. Overall incidence among clinical isolates has been 20Jo and occurs with a frequency of I x 10-• -1 x lo-' as 1 ' sequential multistep mutations leading to: a) alteration of Topisomerase Il of the bacterial DNA b) decreased drug permeation.
The development of resistance may be related to the presence of barely inhibitory or subinhibitory concentration of the antibiotic preventing eradication and encouraging growth of clones of resistant strains.
Ciprofloxacin is effective against both methicillinsensitive and methicillfa-resistant Staphylococcus aureus (MRSA), coagulase-positive or coagulasenegative Staphylococcus aureus and promises to be an alternative to vancomycin for MRSA.
11 However, New York City hospitals showed an increase in the resistant strains of Staphylococcus aureus from 0.9% to 5.3% within a year after the introduction of ciprofloxacin to these hospitals. 17 Some authors are concerned that this resistance may spread from person to person, 11 particularly with MRSA. ln summary, it is clear that sequential intravenous/oral ciprofloxacin is very effective in the treatment of lower respiratory tract infection. Early institution of oral ciprofloxacin after a course of intravenous therapy is safe and can result in significant cost savings. With persistent pseudomonal and staphylococcal infections, the chances of emergence of drug resistance are present. To minimize this, it is extremely important to use this important new drug only in the proper settings, in adequate doses and not as an empiric treatment of respiratory infections, particularly those related to MRSA.
